News Release

<< Back

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

06/01/07

SOUTH SAN FRANCISCO, Calif., June 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology Association (EHA) being held June 7-10, 2007 in Vienna, Austria.

Presentations will include updated interim data from the company's Phase 1 clinical trial of SNS-595 in acute leukemias, as well as clinical data from an ongoing study of SNS-032 further detailing that compound's mechanism of action.

    -- Abstract #0489: "Pharmacokinetic/Pharmacodynamic Correlation with
       Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute
       Leukemias Treated with SNS-595" will be presented on Saturday, June 9,
       2007 from 6:00-7:15 p.m. during the Acute Myeloid Leukemia -- Clinical
       II poster session.

    -- Abstract #0742: "SNS-032 Exhibits Dose-Dependent Mechanism-Based
       Inhibition of CDK7 and CDK9 in Peripheral Blood Mononuclear Cells from
       Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial"
       will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during
       the Novel Therapeutics and Targeted Therapies poster session.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute leukemias for its lead compound, SNS-595. SNS-032, a selective inhibitor of cyclin-dependent kinases 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314, is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SOURCE Sunesis Pharmaceuticals, Inc.

Investors, Eric Bjerkholt, SVP, Corporate Development & Finance of Sunesis
Pharmaceuticals, Inc., +1-650-266-3717; or Karen L. Bergman, +1-650-575-1509, or
Michelle Corral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals,
Inc.
http://www.sunesis.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX